Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrew Bruce McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Zaucha, Vladimir Ivanov, Vladimir Melnichenko, Heidi Mocikova, Muhit Ozcan, Caterina Patti, Joao Farias, Iara Goncalves, Jiří Mayer, Guray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Katherine Ryland, Samhita Chakraborty, Wojciech Jurczak
Institutions: University of Cape Town, Groote Schuur Hospital, Policlinico San Matteo Fondazione, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Gdańsk Medical University, Federal Almazov North-West Medical Research Centre, National Medical and Surgical Center named after N.I. Pirogov, University Hospital Kralovske Vinohrady, Ankara University, Ospedale Vincenzo Cervello, Hospital Erasto Gaertner, Hospital de Câncer de Barretos, Masaryk University, University Hospital Brno, Ege University, Ege Üniversitesi Tıp Fakültesi Hastanesi, Harbor–UCLA Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379345850